The Pontine Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pontine Glioma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued products.

GlobalData tracks 66 drugs in development for Pontine Glioma by 61 companies/universities/institutes. The top development phase for Pontine Glioma is phase i with 27 drugs in that stage. The Pontine Glioma pipeline has 52 drugs in development by companies and 14 by universities/ institutes. Some of the companies in the Pontine Glioma pipeline products market are: Bristol-Myers Squibb, Novartis and Seattle Children’s Hospital.

The key targets in the Pontine Glioma pipeline products market include Cells Expressing CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276), Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22), and Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22).

The key mechanisms of action in the Pontine Glioma pipeline product include Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Inhibitor with three drugs in Phase II. The Pontine Glioma pipeline products include 13 routes of administration with the top ROA being Oral and 11 key molecule types in the Pontine Glioma pipeline products market including Small Molecule, and Subunit Vaccine.

Pontine Glioma overview

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, drooping of one side of the face, and difficulty chewing and swallowing.

For a complete picture of Pontine Glioma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.